Tweet
Pharma Investments, Ventures & Law Weekly
October 14, 2007
CHEMOTHERAPY;
Studies from T.K. Davtyan and colleagues reveal new findings on
chemotherapy
Pg. 821
"The systemic therapeutic application of iodophores has not yet been
accepted due to limited availability of safe and effective ionized
iodine preparations (see also Chemotherapy). Here we evaluated the
antibacterial activity of iodine-lithium-ei-dextrin (lL alpha D) both
in vitro and in vivo," researchers in Yerevan, Armenia report.
"The MIC values of IL alpha D against 189 bacterial isolates in
various growth media and in vivo toxicity and protective efficacy of
IL alpha D in preventing mortality of rats infected with
Staphylococcus aureus were determined. The intracellular killing of
S. aureus by neutrophils in the presence of IL alpha D and
myeloperoxidase (MPO)-catalysed oxidation of iodide was also
determined. The MIC values of IL alpha D against 189 Gram-positive
cocci and Gram-negative bacilli ranged between 124-512 mg/L in growth
media and 6.2-12.5 mg/L in buffer solution, and were highly variable
in the presence of amino -acids. We observed protection of S.
aureus-infected rats from death with significant reduction of
bacterial growth in organs upon intravenous administration of IL
alpha D at doses that are 4-12 times lower than maximal in vivo
tolerability dose. Intracellular killing of S. aureus by neutrophils
increased in the presence of IL alpha D probably due to MPO-catalysed
oxidation of iodide into hypoiodous acid. The pattern of IL alpha D
reaction with amino acids at different pH or halide ion content
determined both the generation of long-lived secondary oxidants and
antibacterial activity. Systemic application of IL alpha D proved to
be successful in the rat infection model by promoting host defence,"
wrote T.K. Davtyan and colleagues.
The researchers concluded: "Probable mechanisms are increased
intracellular killing of bacteria by production of hypoiodous acid
and iodamines as well as anti-inflammatory activity."
Davtyan and colleagues published their study in the Journal of
Antimicrobial Chemotherapy (Evaluation of amino acids as mediators
for the antibacterial activity of iodine-lithium-alpha-dextrin in
vitro and in vivo. Journal of Antimicrobial Chemotherapy,
2007;59(6):1114-1122).
For additional information, contact T.K. Davtyan, Armenicum Research
Center, Laboratory Immunology & Virology, Yerevan, Armenia.
Publisher contact information for the Journal of Antimicrobial
Chemotherapy is: Oxford University Press, Great Clarendon St., Oxford
OX2 6DP, England.
Keywords: Armenia, Yerevan, Amino Acids, Antibacterial Activity,
Antibiotics, Antimicrobials, Chemotherapy, Drug Therapy, Drugs,
Enzyme Research, Lithium, Myeloperoxidase, Pharmaceuticals, Therapy,
Treatment.
This article was prepared by Pharma Investments, Ventures & Law Week
editors from staff and other reports. Copyright 2007, Pharma
Investments, Ventures & Law Week via Chemotherapy.
October 14, 2007
CHEMOTHERAPY;
Studies from T.K. Davtyan and colleagues reveal new findings on
chemotherapy
Pg. 821
"The systemic therapeutic application of iodophores has not yet been
accepted due to limited availability of safe and effective ionized
iodine preparations (see also Chemotherapy). Here we evaluated the
antibacterial activity of iodine-lithium-ei-dextrin (lL alpha D) both
in vitro and in vivo," researchers in Yerevan, Armenia report.
"The MIC values of IL alpha D against 189 bacterial isolates in
various growth media and in vivo toxicity and protective efficacy of
IL alpha D in preventing mortality of rats infected with
Staphylococcus aureus were determined. The intracellular killing of
S. aureus by neutrophils in the presence of IL alpha D and
myeloperoxidase (MPO)-catalysed oxidation of iodide was also
determined. The MIC values of IL alpha D against 189 Gram-positive
cocci and Gram-negative bacilli ranged between 124-512 mg/L in growth
media and 6.2-12.5 mg/L in buffer solution, and were highly variable
in the presence of amino -acids. We observed protection of S.
aureus-infected rats from death with significant reduction of
bacterial growth in organs upon intravenous administration of IL
alpha D at doses that are 4-12 times lower than maximal in vivo
tolerability dose. Intracellular killing of S. aureus by neutrophils
increased in the presence of IL alpha D probably due to MPO-catalysed
oxidation of iodide into hypoiodous acid. The pattern of IL alpha D
reaction with amino acids at different pH or halide ion content
determined both the generation of long-lived secondary oxidants and
antibacterial activity. Systemic application of IL alpha D proved to
be successful in the rat infection model by promoting host defence,"
wrote T.K. Davtyan and colleagues.
The researchers concluded: "Probable mechanisms are increased
intracellular killing of bacteria by production of hypoiodous acid
and iodamines as well as anti-inflammatory activity."
Davtyan and colleagues published their study in the Journal of
Antimicrobial Chemotherapy (Evaluation of amino acids as mediators
for the antibacterial activity of iodine-lithium-alpha-dextrin in
vitro and in vivo. Journal of Antimicrobial Chemotherapy,
2007;59(6):1114-1122).
For additional information, contact T.K. Davtyan, Armenicum Research
Center, Laboratory Immunology & Virology, Yerevan, Armenia.
Publisher contact information for the Journal of Antimicrobial
Chemotherapy is: Oxford University Press, Great Clarendon St., Oxford
OX2 6DP, England.
Keywords: Armenia, Yerevan, Amino Acids, Antibacterial Activity,
Antibiotics, Antimicrobials, Chemotherapy, Drug Therapy, Drugs,
Enzyme Research, Lithium, Myeloperoxidase, Pharmaceuticals, Therapy,
Treatment.
This article was prepared by Pharma Investments, Ventures & Law Week
editors from staff and other reports. Copyright 2007, Pharma
Investments, Ventures & Law Week via Chemotherapy.